USPTO Art Unit 1622 Prosecution Statistics

Art Unit Information

Art Unit: 1622
Group: 1620
Tech Center: 1600
Total Cases: 13,327
Last Active: September 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19323422PHARMACEUTICAL COMPOSITION FOR KERATOSIS AND USE THEREOFSeptember 2025March 2026Allow601YesNo
19299240COMBINATION THERAPY WITH CLK/DYRK INHIBITORS AND BCL2 INHIBITORS TO TREAT LEUKEMIAAugust 2025February 2026Allow602YesNo
19295468INHIBITION OF GLIAL CELL ACTIVATIONAugust 2025January 2026Allow601YesNo
19281069SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUNDJuly 2025January 2026Allow600YesNo
19274086TOPICAL FORMULATION FOR A JAK INHIBITORJuly 2025January 2026Allow600YesNo
19231354OPHTHALMIC COMPOSITIONS FOR TREATMENT OF OCULAR SURFACE DAMAGE AND SYMPTOMS OF DRYNESSJune 2025March 2026Abandon910NoNo
19212445COMPOSITIONS AND METHODS FOR TREATMENT OF PERI-IMPLANTITIS AND PERIODONTITISMay 2025August 2025Allow300YesNo
19210898PHARMACEUTICAL DOSAGE FORMS AND METHODS OF USEMay 2025January 2026Allow811YesNo
19204186AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOFMay 2025January 2026Allow801YesNo
19195185SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTSApril 2025November 2025Allow711NoNo
19189862INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETOApril 2025December 2025Allow810YesNo
19182010COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONSApril 2025November 2025Allow710YesNo
19182366PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFApril 2025October 2025Allow611YesNo
19176900ARSINOTHRICIN AND METHODS OF TREATING INFECTIONS USING ARSINOTHRICINApril 2025May 2025Allow100YesNo
19173537NOVEL COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONSApril 2025August 2025Allow511YesNo
19171214TOPICAL FORMULATION FOR JAK INHIBITORApril 2025October 2025Allow601YesNo
19080373COMPOUND AS VOLTAGE-GATED SODIUM CHANNEL INHIBITORMarch 2025July 2025Allow400NoNo
19079010SOLID STATE FORMS OF A KINASE INHIBITORMarch 2025September 2025Allow610NoNo
19072501HETEROCYCLIC SUBSTITUTED PYRIMIDOPYRAN COMPOUND AND USE THEREOFMarch 2025November 2025Allow811NoNo
19060423FAST ABSORBING TROLAMINE SALICYLATE FORMULATIONS AND COMPOSITIONSFebruary 2025October 2025Allow701YesNo
19047053ORAL LIQUID FORMULATION OF RIVAROXABANFebruary 2025February 2026Allow1221YesNo
190381371-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDSJanuary 2025December 2025Allow1010NoNo
19032963PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3,-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFJanuary 2025August 2025Allow711YesNo
18995170BIDENTATE PHOSPHITE LIGANDS, CATALYTIC COMPOSITIONS CONTAINING SUCH LIGANDS, AND CATALYTIC PROCESSES UTILIZING SUCH CATALYTIC COMPOSITIONSJanuary 2025December 2025Allow1100YesNo
19018731PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERSJanuary 2025March 2025Allow200YesNo
19016312READY-TO-USE NON-AQUEOUS ORAL SOLUTION OF LOSARTANJanuary 2025August 2025Allow710YesNo
19012616ORAL LIQUID FORMULATION OF METHOCARBAMOLJanuary 2025July 2025Allow610NoNo
19009660TREM2 MODULATORSJanuary 2025August 2025Allow820YesNo
19009637TREM2 MODULATORSJanuary 2025May 2025Allow501YesNo
18987568SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUNDDecember 2024June 2025Allow601YesNo
18988090SYNTHESIS OF KRAS G12C INHIBITOR COMPOUNDDecember 2024June 2025Abandon610NoNo
18988163SYNTHESIS OF KRAS G12C INHIBITOR COMPOUNDDecember 2024June 2025Abandon610NoNo
18985720DITHIENYL DISULFIRAM DERIVATIVES AS SELECTIVE ALDH1A1 INHIBITORSDecember 2024May 2025Allow510YesNo
18974530Preparation Method and Application of Micelle Preparation Containing Thymol and Derivative ThereofDecember 2024March 2025Allow300YesNo
18973200RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARISDecember 2024September 2025Allow920YesNo
18972606USE OF ANDROGEN RECEPTOR DEGRADER FOR THE TREATMENT OF SPINAL AND BULBAR MUSCULAR ATROPHYDecember 2024October 2025Allow1120YesNo
18968074EMULSIFIABLE NEONICOTINOID PESTICIDE CONCENTRATEDecember 2024February 2025Allow300YesNo
18964259USE OF CHIDAMIDE IN PREPARING DRUG FOR TREATING RENAL FIBROSISNovember 2024July 2025Allow811YesNo
18961657METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSISNovember 2024August 2025Allow910YesNo
18957414BIS UREA-BASED ORGANOSELENIUM COMPOUND AND METHOD FOR TREATING CANCERNovember 2024June 2025Allow711YesNo
18954406ORGANOSELENIUM COMPOUND FOR TREATING CANCERNovember 2024August 2025Allow911NoNo
189498014H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDSNovember 2024January 2026Abandon1411NoNo
18941896Progestin/Testosterone Transdermal GelNovember 2024August 2025Allow921YesNo
18934749STABLE LEVOTHYROXINE COMPOSITIONS IN APROTIC POLAR SOLVENTSNovember 2024November 2025Allow1320YesNo
18927346COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVESOctober 2024April 2025Allow611YesNo
18923566MrgprX2 Antagonists for the Treatment of Inflammatory DisordersOctober 2024September 2025Allow1122YesNo
18915221AZAINDOLE ROCK INHIBITORSOctober 2024January 2025Allow300NoNo
18913645PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFOctober 2024April 2025Allow611NoNo
18912939RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARISOctober 2024August 2025Abandon1010NoNo
18910967NOVEL COMPOUNDSOctober 2024February 2026Allow1612NoNo
18905898METHOD OF TREATING HAIR LOSS DISORDERSOctober 2024March 2025Allow500YesNo
18895223METHOD OF TREATING CANCER IN A SUBJECTSeptember 2024March 2025Allow601YesNo
18884931METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONSSeptember 2024August 2025Abandon1110YesNo
18884941METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONSSeptember 2024March 2026Abandon1830YesNo
18882644QUINOLINONE AMIDE COMPOUNDS AND USES THEREOFSeptember 2024April 2025Allow811NoNo
18882652QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOFSeptember 2024October 2025Allow1321YesNo
18827538PHARMACEUTICAL COMPOSITIONS COMPRISING A MENIN INHIBITORSeptember 2024September 2025Allow1321YesNo
18820199NAPHTHALENE ISOXAZOLINE COMPOUND AND APPLICATION THEREOFAugust 2024December 2024Allow400YesNo
18814130PHARMACEUTICAL RECTAL SUPPOSITORY COMPOSITIONS OF 6-THIOGUANINE, METHODS OF TREATMENT AND/OR METHODS OF MANUFACTURINGAugust 2024January 2026Allow1721YesNo
18812527MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOFAugust 2024March 2025Allow711YesNo
18807584FORMULATIONS OF AMINOPENICILLIN AND METHODS FOR SOLUBILIZING AMINOPENICILLINAugust 2024May 2025Allow920YesNo
18805702Diagnosis and Treatment of VitiligoAugust 2024May 2025Allow911YesNo
18723881SALT FORM AND CRYSTAL FORM OF TETRAHYDROCYCLOHEPTA INDAZOLE COMPOUNDAugust 2024May 2025Allow1010YesNo
18794128AMLODIPINE FORMULATIONSAugust 2024April 2025Allow811NoNo
18793674ENTHESIS HEALINGAugust 2024November 2025Allow1611YesNo
18792836METHODS OF TREATING BRAIN DISORDERSAugust 2024May 2025Allow911NoNo
18787515RESINIFERATOXIN COMPOSITIONSJuly 2024January 2026Abandon1831YesNo
18782646ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONSJuly 2024October 2025Allow1521YesNo
18832280BENZOISOTHIAZOLE AND BENZOISOXAZOLE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERSJuly 2024February 2025Allow700YesNo
18778226PHARMACEUTICAL COMPOSITIONS COMPRISING TIMOLOLJuly 2024December 2025Allow1730YesNo
18777888PRODRUGS OF ITACONATE AND METHYL ITACONATEJuly 2024September 2025Allow1621YesNo
18776438METHOD OF USING ILOPROST FOR TREATING FROSTBITEJuly 2024July 2025Allow1220YesNo
18776040PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFJuly 2024January 2025Allow620YesNo
18768656TOPICAL OPHTHALMOLOGICAL COMPOSITIONSJuly 2024August 2025Allow1310YesNo
18764507SULFORAPHANE-CYSTEINE FOR WOUND HEALING IN DIABETIC SUBJECTSJuly 2024November 2024Allow400YesNo
18725257IONIC-LIQUID-BASED FORMULATIONS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASESJune 2024August 2025Allow1420NoNo
18759222TOPICAL FORMULATIONS FOR INFECTIONSJune 2024November 2025Allow1721YesNo
18722753DIHYDRO-OXAZOL DERIVATIVE COMPOUNDSJune 2024March 2026Abandon2021YesNo
18750014METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORSJune 2024March 2025Allow910NoNo
18750032METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORSJune 2024April 2025Allow1010NoNo
18747376SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2June 2024July 2025Allow1311NoNo
18744484NOVEL COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONSJune 2024May 2025Allow1110NoNo
18743233PHARMACEUTICAL COMBINATIONS FOR TREATING CANCERJune 2024May 2025Allow1110NoNo
18743475SARS-COV2 MAIN PROTEASE INHIBITORSJune 2024April 2025Allow1110NoNo
18743025ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOFJune 2024March 2025Allow920NoNo
18742375COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASEJune 2024February 2026Allow2011NoNo
18735898SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDSJune 2024February 2026Allow2011NoNo
18734105PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFJune 2024December 2024Allow611NoNo
18680558KIF18A INHIBITORSMay 2024July 2025Allow1311NoNo
18675584PIKfyve InhibitorsMay 2024June 2025Abandon1210NoNo
18674233MIRDAMETINIB TREATMENTMay 2024September 2024Allow410YesNo
18674168MIRDAMETINIB TREATMENTMay 2024January 2025Allow810NoNo
18674104MIRDAMETINIB TREATMENTMay 2024June 2025Abandon1210NoNo
18710989MELAMINE PROCESS WITH A TWO-STAGE PURIFICATION OF MELAMINE OFFGASMay 2024June 2025Allow1300NoNo
18660829THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS AND USES THEREOFMay 2024April 2025Allow1111NoNo
18661306METHOD OF TREATING SEIZURES AND EPILEPSY USING LIQUID PHARMACEUTICAL COMPOSITION FOR ORAL DOSAGE OF VIGABATRINMay 2024September 2025Allow1710NoNo
18659957TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASESMay 2024December 2025Abandon1901NoNo
18658848METHODS AND COMPOSITIONS FOR TARGETING PD-L1May 2024September 2025Allow1611YesNo
18654235BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORSMay 2024January 2026Allow2011NoNo
18652993RAMIPRIL SOLUTION FOR ORAL DOSAGEMay 2024May 2025Allow1221YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1622.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
47
Examiner Affirmed
20
(42.6%)
Examiner Reversed
27
(57.4%)
Reversal Percentile
96.0%
Higher than average

What This Means

With a 57.4% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
419
Allowed After Appeal Filing
157
(37.5%)
Not Allowed After Appeal Filing
262
(62.5%)
Filing Benefit Percentile
78.3%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 37.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1622 - Prosecution Statistics Summary

Executive Summary

Art Unit 1622 is part of Group 1620 in Technology Center 1600. This art unit has examined 13,327 patent applications in our dataset, with an overall allowance rate of 79.7%. Applications typically reach final disposition in approximately 22 months.

Comparative Analysis

Art Unit 1622's allowance rate of 79.7% places it in the 61% percentile among all USPTO art units. This art unit has an above-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1622 receive an average of 1.31 office actions before reaching final disposition (in the 12% percentile). The median prosecution time is 22 months (in the 90% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more favorable examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.